Are symptoms and clinical findings at the time of diagnosis of recurrent head and neck cancer associated with disease outcomes?
In this cohort study of 196 patients, 1-year overall survival was 58.2% (114 of 196 patients). The clinical variables of time to recurrence and symptom severity stage were combined with rTNM stage to create a new 3-category staging system; the discriminative power of this new composite staging was better than that of the American Joint Committee on Cancer classification.
Symptoms and clinical variables may be associated with anticipation of outcomes in patients with recurrent head and neck cancer.
Despite advances in treatment over the last decades, recurrent head and neck cancer continues to have a poor prognosis. Prognostic accuracy may help in patient counseling.
To explore whether symptoms and clinical variables can predict prognosis in the setting of recurrent head and neck cancer.
Design, Setting, and Participants
In this retrospective cohort study, patients treated for head and neck cancer with curative intent at Siteman Cancer Center in St Louis, Missouri (a tertiary cancer center) between January 1, 2007, and December 31, 2014, were reviewed. The dates of data analysis were October 2016 to June 2017. Patients who developed a recurrent cancer were included, with 196 patients meeting inclusion criteria.
Main Outcomes and Measures
Symptoms and clinical findings at presentation of recurrence were recorded. Sequential sequestration and conjunctive consolidation (2 multivariable techniques) were used to create a composite staging system to predict 1-year overall survival (OS).
Among 196 patients (mean [SD] age, 61  years; 166 [84.7%] of white race/ethnicity; 76.5% male), 1-year OS was 58.2% (114 of 196 patients). Time to recurrence, symptom severity stage, and rTNM stage were consolidated into a 3-category Clinical Severity Staging System, with 1-year OS rates of 90.2% (95% CI, 82.7%-97.6%) for the 61 patients classified as A, 58.1% (95% CI, 47.7%-68.6%) for the 86 patients classified as B, and 18.4% (95% CI, 7.5%-29.2%) for the 49 patients classified as C. The discriminative power of the new composite staging was better than that of the American Joint Committee on Cancer classification (C = 0.79 vs C = 0.66).
Conclusions and Relevance
These findings suggest that clinical variables are associated with anticipated outcomes in patients with recurrent head and neck cancer.
Pipkorn P, Licata J, Kallogjeri D, Piccirillo JF. Association of Symptoms and Clinical Findings With Anticipated Outcomes in Patients With Recurrent Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2018;144(8):738–745. doi:10.1001/jamaoto.2018.1230
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: